Dos of Afentanil 20

PreclinicalSmall molecule

TTongji Hospital

Dos of Afentanil 20 is one of 3 small molecule programs targeting Remimazolam Besylate. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Remimazolam BesylateUnknown status

Remimazolam BesylatePreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Remimazolam Besylate

#DrugCompanyPhaseTrials

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3

3 2

Remazolam Besylate

FFirst Affiliated Hospital of Ningbo University

Phase 3

1 3

Dos of Afentanil 20

TTongji Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Remimazolam Besylate1 trial

Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI

Unknown status·TTongji Hospital·N/A·NCT06026566·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dos of Afentanil 20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dos of Afentanil 20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dos of Afentanil 20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTongji Hospital

Dos of Afentanil 20

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Remimazolam Besylate1 trial

References

Drug Info

Quick Facts

Related News